Globus Medical (NYSE:GMED) Issues FY 2025 Earnings Guidance

Globus Medical (NYSE:GMED - Get Free Report) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided EPS guidance of 3.000-3.300 for the period, compared to the consensus EPS estimate of 3.164. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.9 billion. Globus Medical also updated its Q2 2025 guidance to EPS.

Globus Medical Price Performance

Shares of GMED traded up $1.18 during trading hours on Tuesday, hitting $53.07. The stock had a trading volume of 2,287,390 shares, compared to its average volume of 1,182,677. Globus Medical has a 1-year low of $51.87 and a 1-year high of $94.93. The firm has a market capitalization of $7.18 billion, a P/E ratio of 39.61, a price-to-earnings-growth ratio of 1.64 and a beta of 1.19. The firm has a 50 day simple moving average of $58.74 and a 200-day simple moving average of $71.89.

Globus Medical (NYSE:GMED - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical device company reported $0.68 EPS for the quarter, missing the consensus estimate of $0.74 by ($0.06). The firm had revenue of $598.12 million for the quarter, compared to the consensus estimate of $629.74 million. Globus Medical had a return on equity of 10.52% and a net margin of 7.39%. Globus Medical's quarterly revenue was down 1.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.72 EPS. Equities analysts predict that Globus Medical will post 3.44 EPS for the current fiscal year.

Globus Medical declared that its Board of Directors has approved a stock repurchase plan on Thursday, May 15th that permits the company to buyback $500.00 million in shares. This buyback authorization permits the medical device company to purchase up to 6.3% of its shares through open market purchases. Shares buyback plans are usually an indication that the company's management believes its stock is undervalued.

Analyst Upgrades and Downgrades

GMED has been the topic of several research analyst reports. Piper Sandler reduced their price target on shares of Globus Medical from $100.00 to $80.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. Morgan Stanley cut their price objective on shares of Globus Medical from $75.00 to $68.00 and set an "overweight" rating on the stock in a report on Tuesday, July 15th. Truist Financial cut their price target on shares of Globus Medical from $80.00 to $68.00 and set a "hold" rating on the stock in a report on Monday, May 12th. JMP Securities reiterated a "market perform" rating on shares of Globus Medical in a report on Tuesday, May 27th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Globus Medical in a report on Monday. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $90.09.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp raised its position in shares of Globus Medical by 237.3% in the first quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company's stock worth $62,000 after acquiring an additional 598 shares during the period. Integrated Wealth Concepts LLC raised its position in shares of Globus Medical by 33.0% in the first quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company's stock worth $320,000 after acquiring an additional 1,085 shares during the period. AQR Capital Management LLC raised its position in shares of Globus Medical by 45.9% in the first quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company's stock worth $1,622,000 after acquiring an additional 7,086 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Globus Medical by 38.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company's stock worth $2,228,000 after acquiring an additional 8,540 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Globus Medical by 8.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company's stock worth $25,439,000 after purchasing an additional 28,027 shares in the last quarter. 95.16% of the stock is currently owned by institutional investors and hedge funds.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.